CYTALUX (pafolacianine)
Ovarian Cancer
Key Facts
About On Target Laboratories
On Target Laboratories is a privately-held diagnostics company pioneering intraoperative molecular imaging agents to improve surgical oncology outcomes. Founded in 2011 and based in West Lafayette, Indiana, the company has advanced its lead agent, CYTALUX®, which targets folate receptor-alpha (FRα) positive cancers. Their platform utilizes small-molecule technology for rapid targeting and flexible dosing, with the goal of reducing residual disease and improving patient survival. The company's pipeline targets major cancer types including ovarian, lung, prostate, and colorectal cancers, addressing a significant unmet need in surgical precision.
View full company profileAbout On Target Laboratories
On Target Laboratories is a privately-held diagnostics company pioneering intraoperative molecular imaging agents to improve surgical oncology outcomes. Founded in 2011 and based in West Lafayette, Indiana, the company has advanced its lead agent, CYTALUX®, which targets folate receptor-alpha (FRα) positive cancers. Their platform utilizes small-molecule technology for rapid targeting and flexible dosing, with the goal of reducing residual disease and improving patient survival. The company's pipeline targets major cancer types including ovarian, lung, prostate, and colorectal cancers, addressing a significant unmet need in surgical precision.
View full company profileAbout On Target Laboratories
On Target Laboratories is a privately-held diagnostics company pioneering intraoperative molecular imaging agents to improve surgical oncology outcomes. Founded in 2011 and based in West Lafayette, Indiana, the company has advanced its lead agent, CYTALUX®, which targets folate receptor-alpha (FRα) positive cancers. Their platform utilizes small-molecule technology for rapid targeting and flexible dosing, with the goal of reducing residual disease and improving patient survival. The company's pipeline targets major cancer types including ovarian, lung, prostate, and colorectal cancers, addressing a significant unmet need in surgical precision.
View full company profileAbout On Target Laboratories
On Target Laboratories is a privately-held diagnostics company pioneering intraoperative molecular imaging agents to improve surgical oncology outcomes. Founded in 2011 and based in West Lafayette, Indiana, the company has advanced its lead agent, CYTALUX®, which targets folate receptor-alpha (FRα) positive cancers. Their platform utilizes small-molecule technology for rapid targeting and flexible dosing, with the goal of reducing residual disease and improving patient survival. The company's pipeline targets major cancer types including ovarian, lung, prostate, and colorectal cancers, addressing a significant unmet need in surgical precision.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |